Noble Heart Failure Therapy Using Food Compositions

DOI Web Site Web Site PubMed 4 Citations 36 References Open Access
  • Morimoto Tatsuya
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, Kyoto Medical Center, National Hospital Organization Shizuoka General Hospital
  • Funamoto Masafumi
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, Kyoto Medical Center, National Hospital Organization
  • Sunagawa Yoichi
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, Kyoto Medical Center, National Hospital Organization Shizuoka General Hospital
  • Katanasaka Yasufumi
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, Kyoto Medical Center, National Hospital Organization Shizuoka General Hospital
  • Miyazaki Yusuke
    Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Division of Translational Research, Kyoto Medical Center, National Hospital Organization Shizuoka General Hospital
  • Hasegawa Koji
    Division of Translational Research, Kyoto Medical Center, National Hospital Organization

Bibliographic Information

Other Title
  • 食品成分による心不全治療の可能性
  • Symposium Review 食品成分による心不全治療の可能性
  • Symposium Review ショクヒン セイブン ニ ヨル シンフゼン チリョウ ノ カノウセイ

Search this article

Abstract

<p>　Hemodynamic stresses, including hypertension and myocardial infarction, activate neurohumoral factors such as the sympathetic nervous system and the renin-angiotensin system, and can lead to the progression of heart failure. Established pharmacological agents such as angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and β-blockers target extra-cellular molecules and receptors on the cell membrane. These agents have shown some efficacy for the treatment of heart failure, but the long-term survival rate of patients with heart failure remains low. Additional effective pharmacological approaches are urgently required. Our previous studies have demonstrated that curcumin, a natural polyphenol derived from the root of Curcuma longa, prevented the development of heart failure in rat models of myocardial infarction and hypertensive heart disease. However, until recently curcumin's poor water solubility and extremely low bioavailability have presented serious challenges to its clinical applicability. In recent years, highly absorbable curcumin preparations have been developed using methods such as nanoparticle formation and micellization, and there are now high expectations for their wide clinical application. Our group has developed a highly absorbable curcumin formulation called Theracurmin using nanoparticulation and surface processing techniques. Our preliminary data indicated that Theracurmin may improve left ventricular diastolic function. Furthermore, we have already completed and are currently carrying out several clinical trials using Theracurmin against heart failure-related diseases. This paper summarizes and discusses the potential clinical applications of curcumin, focusing on our highly absorbable curcumin formulation, Theracurmin.</p>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 138 (10), 1263-1269, 2018-10-01

    The Pharmaceutical Society of Japan

Citations (4)*help

See more

References(36)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top